For a limited time upgrade to TradeZing+ to browse the platform without any ads and gain access to our latest AI powered tools
Subscribe to TradeZing+ Learn MoreDecember 2, 2023
3 mins ago
Nutanix (NTNX) shares are seeing a boost this morning after topping fiscal first-quarter earnings estimates. Nutanix CEO Rajiv …
0107961
YouTube
December 2, 2023
3 mins ago
Try Margex to long or short crypto! NO KYC. Use code: MFF20 This gives a 20% bonus on deposits, up to $10000 to be used to …
0107960
YouTube
December 2, 2023
1 hour ago
Get The Hottest Crypto Deals https://www.coinbureau.com/deals/ ♣️ Coin Bureau Club https://hub.coinbureau.com/ …
0107959
YouTube
2 weeks ago
BETHESDA, Md., Nov. 21, 2023 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the pricing of an underwritten public offering of 2,213,044 shares of its common stock and warrants to purchase up to an aggregate of 1,106,522 shares of its common stock at a combined public offering price of $2.005 per share and accompanying warrant. The public offering price for each set of two shares of common stock and accompanying warrant to purchase one share of common stock is $4.01 per set of securities, yielding an effective price of $2.00 per share and $0.01 per warrant. The warrants are being sold at the rate of one warrant for every two shares of common stock. The warrants will have an exercise price of $2.75 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance.
Copied
December 2, 2023
3 mins ago
Nutanix (NTNX) shares are seeing a boost this morning after topping fiscal first-quarter earnings estimates. Nutanix CEO Rajiv …
0107961
YouTube
December 2, 2023
3 mins ago
Try Margex to long or short crypto! NO KYC. Use code: MFF20 This gives a 20% bonus on deposits, up to $10000 to be used to …
0107960
YouTube
December 2, 2023
1 hour ago
Get The Hottest Crypto Deals https://www.coinbureau.com/deals/ ♣️ Coin Bureau Club https://hub.coinbureau.com/ …
0107959
YouTube
Sign up or Log in to Comment